SCHEMBL5745462

SCHEMBL5745462

Cc1ccc(Cl)cc1N1CCN(S(=O)(=O)c2cc(CC(=O)O)ccc2C)CC1

nearest known ligand 0.59

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.59
THRB P10828 1/20 0.59
NPSR1 Q6W5P4 1/20 0.56
LMNA P02545 4/20 0.54
TSHR P16473 1/20 0.54
PTPN11 Q06124 1/20 0.53
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
ALDH1A1 P00352 1/20 0.53
MCOLN3 Q8TDD5 1/20 0.53
USP2 O75604 1/20 0.53
POLB P06746 5/20 0.53
KDM4E B2RXH2 1/20 0.52
TP53 P04637 3/20 0.52
HTT P42858 1/20 0.51
ATM Q13315 1/20 0.51
CYP2C9 P11712 1/20 0.50
CYP2C19 P33261 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5775668 0.89 MAPT (0.53) MAPTLMNATSHRMEN1KMT2A
SCHEMBL5746517 0.88 L3MBTL1 (0.52) MAPTTHRBNPSR1LMNAALDH1A1
SCHEMBL5746076 0.85 LMNA (0.69) MAPTNPSR1LMNATSHRPTPN11
SCHEMBL5749721 0.83 MAPT (0.53) MAPTLMNAALDH1A1MCOLN3POLB
SCHEMBL5798425 0.83 THRB (0.56) MAPTTHRBNPSR1LMNAPTPN11
SCHEMBL6349294 0.81 MAPT (0.52) MAPTTHRBNPSR1LMNAPOLB
SCHEMBL5776077 0.80 GFER (0.45) MAPTTHRBLMNAALDH1A1MCOLN3
SCHEMBL5797718 0.80 GAA (0.57) LMNATSHRMEN1KMT2AALDH1A1
SCHEMBL5773090 0.78 HSD11B1 (0.53) MAPTTHRBLMNAMEN1KMT2A
SCHEMBL5747352 0.77 MAPK1 (0.55) MAPTLMNATSHRPTPN11ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1735280-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS Kalypsys, Inc. (US) 2006-12-27 EP disclosed
WO-2005115983-A1 ARYL SULFONAMIDE AND SULFONYL COMPOUNDS AS MODULATORS OF PPAR AND METHODS OF TREATING METABOLIC DISORDERS KALYPSYS, INC. (US) 2005-12-08 WO disclosed
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders KALYPSYS, INC. (US) 2005-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050234046-A1 Aryl sulfonamide and sulfonyl compounds as modulators of PPAR and methods of treating metabolic disorders PPARA, PPARG, PPARD MAPT 4579/4885THRB 230/4885NPSR1 602/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.